Understanding ERBB2 Overexpression in Non-Breast Cancers
Author Information
Author(s): Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R
Primary Institution: Liège University
Hypothesis
Are the mechanisms of ERBB2 overexpression in breast cancers also present in non-breast cancers?
Conclusion
Different mechanisms lead to ERBB2 overexpression in breast and non-breast cancers.
Supporting Evidence
- ERBB2 is overexpressed in about 30% of breast and ovary cancers.
- The study found moderate ERBB2 overexpression in non-breast cancer cells.
- AP-2 transcription factors do not correlate with ERBB2 expression in non-breast cancers.
- Different regulatory mechanisms for ERBB2 expression were identified in non-breast cancer cells.
Takeaway
This study looks at how a gene called ERBB2 is overactive in different types of cancer, not just breast cancer, and finds that the reasons for this can be different.
Methodology
Cell lines from various cancers were analyzed for ERBB2 gene copy number, mRNA, and protein levels using techniques like immunocytochemistry and real-time PCR.
Limitations
The study primarily focuses on a limited number of cancer types and may not encompass all mechanisms of ERBB2 overexpression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website